Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Looking forward to ISAL 2023

Marion Subklewe • 12 Dec 2022
ISAL 2023
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, shares some insights into the upcoming 18th International Symposium on Acute Leukemias (ISAL XVIII), which is being held in Munich, Germany, on March 19-22, 2023.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marion Subklewe

1:43
CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment
Marion Subklewe • 9 Dec 2023
1:04
MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe • 9 Dec 2023
1:42
Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML
Marion Subklewe • 9 Dec 2023
2:33
Novel immunotherapies in AML and insights into the future of the treatment landscape
Marion Subklewe • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals